David L. Hageman
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by David L. Hageman.
Tetrahedron Letters | 1997
Stephen W. Wright; David L. Hageman; Ann S. Wright; Lester D. McClure
Abstract A one-pot preparation of t-butyl esters and ethers is described that proceeds from the carboxylic acid or alcohol and t-butanol using only anhydrous magnesium sulfate and catalytic sulfuric acid as additional reagents. The method affords t-butyl esters and ethers in good yields and is applicable to a variety of substrates.
Bioorganic & Medicinal Chemistry Letters | 2003
Stephen W. Wright; Anthony A. Carlo; Dennis E. Danley; David L. Hageman; George A. Karam; Mahmoud N. Mansour; Lester D. McClure; Jayvardhan Pandit; Gayle K. Schulte; Judith L. Treadway; Ing-Kae Wang; Paul H. Bauer
3-(2-Carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid (MDL-29951), an antagonist of the glycine site of the NMDA receptor, has been found to be an allosteric inhibitor of the enzyme fructose 1,6-bisphosphatase. The compound binds at the AMP regulatory site by X-ray crystallography. This represents a new approach to inhibition of fructose 1,6-bisphosphatase and serves as a lead for further drug design.
Bioorganic & Medicinal Chemistry Letters | 2001
Stephen W. Wright; David L. Hageman; Lester D. McClure; Anthony A. Carlo; Judith L. Treadway; Alan M. Mathiowetz; Jane M. Withka; Paul H. Bauer
Anilinoquinazolines currently of interest as inhibitors of tyrosine kinases have been found to be allosteric inhibitors of the enzyme fructose 1,6-bisphosphatase. These represent a new approach to inhibition of F16BPase and serve as leads for further drug design. Enzyme inhibition is achieved by binding at an unidentified allosteric site.
Tetrahedron Letters | 1996
Stephen W. Wright; Lester D. McClure; David L. Hageman
Abstract A modification of the Gassman oxindole synthesis is described that proceeds from anilines and ethyl (methylsulfinyl)acetate, using oxalyl chloride to activate the sulfoxide to facilitate the formation of the key N - S bonded intermediate. This procedure is particularly convenient for reactions carried out on smaller scales and for anilines that are susceptible to electrophilic halogenation.
Bioorganic & Medicinal Chemistry Letters | 1992
James J. Valentine; Susumu Nakanishi; David L. Hageman; R.Michael Snider; Robin W. Spencer; Fredric J. Vinick
Abstract CP-70,030 and CP-75,998 were identified in a screening program as compounds able to displace [125I]-gastrin releasing peptide (GRP) from its rat brain receptor. We describe here the syntheses of these compounds and their characterization as bonafide GRP antagonists.
Tetrahedron Letters | 1996
Stephen W. Wright; Robert L. Dow; Lester D. McClure; David L. Hageman
Abstract A synthetic approach to a structurally novel series of indoline 2,2-biscarboxylates is described that employs a tandem bis-alkylation strategy to cyclize the indoline heteroring from the bromide 7 and diethyl bromomalonate. The indolines thus prepared may be N-deprotected and further functionalized on the indoline nitrogen.
Journal of Organic Chemistry | 1994
Stephen W. Wright; David L. Hageman; Lester D. McClure
Journal of Medicinal Chemistry | 2002
Stephen W. Wright; Carlo Aa; Carty; Dennis E. Danley; David L. Hageman; Karam Ga; Levy Cb; Mahmoud N. Mansour; Mathiowetz Am; Lester D. McClure; Nestor Nb; McPherson Rk; Jayvardhan Pandit; Pustilnik Lr; Schulte Gk; Soeller Wc; Judith L. Treadway; Wang Ik; Paul H. Bauer
Journal of Medicinal Chemistry | 1994
John A. Lowe; David L. Hageman; Susan E. Drozda; Stafford McLean; Dianne K. Bryce; Rosemary T. Crawford; Stevin H. Zorn; Jean Morrone; Jon Bordner
Bioorganic & Medicinal Chemistry Letters | 2005
Stephen W. Wright; Virginia L. Rath; Paul E. Genereux; David L. Hageman; Carolyn B. Levy; Lester D. McClure; Scott C. McCoid; R. Kirk McPherson; Teresa M. Schelhorn; Donald E. Wilder; William J. Zavadoski; E. Michael Gibbs; Judith L. Treadway